[{"address1": "4546 El Camino Real", "address2": "Suite B1", "city": "Los Altos", "state": "CA", "zip": "94022", "country": "United States", "phone": "650 284 4433", "fax": "650 397 4433", "website": "https://renovorx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Ms. Leesa  Gentry", "age": 53, "title": "Chief Clinical Officer", "yearBorn": 1970, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 1.27, "open": 1.265, "dayLow": 1.22, "dayHigh": 1.3, "regularMarketPreviousClose": 1.27, "regularMarketOpen": 1.265, "regularMarketDayLow": 1.22, "regularMarketDayHigh": 1.3, "beta": 1.041, "forwardPE": -2.9756098, "volume": 22305, "regularMarketVolume": 22305, "averageVolume": 38538, "averageVolume10days": 11470, "averageDailyVolume10Day": 11470, "bid": 0.9216, "ask": 1.6, "bidSize": 200, "askSize": 200, "marketCap": 29218756, "fiftyTwoWeekLow": 0.531, "fiftyTwoWeekHigh": 3.29, "fiftyDayAverage": 1.36914, "twoHundredDayAverage": 1.334605, "currency": "USD", "enterpriseValue": 19403490, "floatShares": 15821802, "sharesOutstanding": 23949800, "sharesShort": 65482, "sharesShortPriorMonth": 15634, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0027, "heldPercentInsiders": 0.0689, "heldPercentInstitutions": 0.013830001, "shortRatio": 1.04, "shortPercentOfFloat": 0.0028, "bookValue": -0.281, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -10232000, "trailingEps": -0.99, "forwardEps": -0.41, "enterpriseToEbitda": -1.704, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RNXT", "underlyingSymbol": "RNXT", "shortName": "RenovoRx, Inc.", "longName": "RenovoRx, Inc.", "firstTradeDateEpochUtc": 1629984600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "6babfc24-dc5c-3de1-bf9d-2ec73346783e", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.22, "targetHighPrice": 7.0, "targetLowPrice": 3.5, "targetMeanPrice": 4.83, "targetMedianPrice": 4.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 1173000, "totalCashPerShare": 0.07, "ebitda": -11390000, "quickRatio": 0.998, "currentRatio": 1.248, "returnOnAssets": -1.6315401, "returnOnEquity": -6.46981, "freeCashflow": -5439500, "operatingCashflow": -10258000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-04"}]